0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV-546.55%PremiumJul 19, 2024Expiry Date6.34Intrinsic Value100Multiplier-6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Cosmos Health Stock Discussion
Cosmos Health Successfully Submits Tender for C-Scrub Wash Chlorhexidine 4% to Supply NHS Scotland
Cosmos Health (NASDAQ:COSM) has announced that its subsidiary, Decahedron , has successfully submitted a tender to supply NHS Scotland with C-Scrub Wash Chlorhexidine 4%, an antimicrobial wash. The tender is for 'Antiseptic Solutions and Hand Hygiene Products' and is invitation-only. C-Scrub offers immediate and prolonged antimicrobial action for up to 6 hours, ta...
Cosmos Health Signs Distribution Agreement with ProMed Trading for Its Sky Premium Life Food Supplements in QatarCosmos Health (NASDAQ:COSM) has signed a distribution agreement with ProMed Trading Company for its Sky Premium Life food supplement products in Qatar. ProMed, a leading healthcare company in Doha, will handle key functions including regulatory compliance, product registration, distribution, promotion, marketing, logistics, and sales in pharmacies and shop...
Cosmos Health Inc., a diversified, vertically integrated global healthcare group, has made strides in expanding its contract manufacturing capabilities through its wholly-owned subsidiary, Cana Laboratories. The company recently announced a new agreement with Prov...
Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Rule
Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units
Cosmos Health (NASDAQ:COSM) announced that its subsidiary, Cana Laboratories, has secured additional contract manufacturing agreements with Provident Pharmaceuticals. The new orders include:
408,000 units of MIOREL for muscle spasms
222,000 units of CALCIFOLIN for nucleic acid synthesis
72,000 units...
Cosmos Health Advances Commercialization of CCX0722 Weight Management Solution with Completion of Pilot Production and Scale-Up Phases; Significant Step Towards Entering $143Bn Global Market
Cosmos Health (NASDAQ:COSM) announced the successful completion of the pilot production and scale-up phases for its weight management solution, CCX0722, a biocompatible hydrogel. These milestones mark the end of the development phase, following earlier project updates such as the...
No comment yet